A Phase 1 Dose-Escalation Study to Determine the Safety of TH-302 in Combination With Sunitinib in Patients With Advanced Renal Cell Carcinoma, Gastrointestinal Stromal Tumors and Pancreatic Neuroendocrine Tumors.

Trial Profile

A Phase 1 Dose-Escalation Study to Determine the Safety of TH-302 in Combination With Sunitinib in Patients With Advanced Renal Cell Carcinoma, Gastrointestinal Stromal Tumors and Pancreatic Neuroendocrine Tumors.

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 Jun 2014

At a glance

  • Drugs Evofosfamide (Primary) ; Sunitinib
  • Indications Gastrointestinal stromal tumours; Neuroendocrine tumours; Pancreatic cancer; Renal cancer; Renal cell carcinoma
  • Focus Adverse reactions
  • Sponsors Threshold Pharmaceuticals
  • Most Recent Events

    • 18 Apr 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 17 Dec 2013 Planned End Date changed from 1 Jun 2013 to 1 Jun 2014 as per ClinicalTrials.gov record.
    • 23 Oct 2013 Results for the phase I part of the study presented at the 25th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top